 | |
| Clinical data | |
|---|---|
| Trade names | Oxbryta |
| Other names | GBT440, GBT-440 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a620011 |
| License data | |
| Routes of administration | By mouth |
| Drug class | Hemoglobin S polymerization inhibitor[1] |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C19H19N3O3 |
| Molar mass | 337.379 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Voxelotor, sold under the brand name Oxbryta, is a medication used to treat sickle cell disease.[1] Evidence shows that it improves hemoglobin levels; however, overall benefits are unclear as of 2021.[1] It is taken by mouth.[1]
Common side effects include headache, abdominal pain, rash, fever, and tiredness.[1] Severe side effects may include allergic reactions.[1] Use in pregnancy is of unclear safety.[2] It is believed to work by improving the ability of abnormal hemoglobin to carry oxygen.[3]
Voxelotor was approved for medical use in the United States in 2019.[1] In Europe it was granted orphan designation in 2016.[3] In the United States it costs about 10,100 USD per month as of 2021.[4]
References edit
- ^ a b c d e f g h i j "Voxelotor Monograph for Professionals". Drugs.com. Retrieved 16 September 2021.
- ^ "Voxelotor (Oxbryta) Use During Pregnancy". Drugs.com. Archived from the original on 21 September 2020. Retrieved 16 September 2021.
- ^ a b "EU/3/16/1769: 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (voxelotor)". Archived from the original on 22 September 2021. Retrieved 16 September 2021.
- ^ "Oxbryta Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 26 January 2021. Retrieved 16 September 2021.